CAP has also been shown to manifest anti-hyperglycemic and anti-obesity effects by modulating the gut–brain axis and inhibiting the entero-hepatic FXR-FGF15 axis. The gene discussed is NR1H4; the disease is obesity due to melanocortin 4 receptor deficiency.